Epithelial-to-mesenchymal transition (EMT) causes fibrosis, cancer progression and metastasis. Integrin-linked kinase (ILK) is a focal adhesion adaptor and a serine/threonine protein kinase that regulates cell proliferation, survival and EMT. Elucidating the molecular mechanisms necessary for development and progression of human malignancies is critical to predict the most appropriate targets for cancer therapy. Here, we used transforming growth factor beta-1 (TGFb-1) to promote EMT and migration in mammary epithelial cells. We demonstrate a requirement of ILK activity for TGFb-1-mediated EMT in mammary epithelial cells. In addition to nuclear translocation of Snail and Slug, TGFb-1 treatment also induced expression of the mammalian target of rapamycin complex 2 component Rictor and its phosphorylation on Thr1135. Interestingly, TGFb-1 treatment also induced an interaction between ILK and Rictor. All of these TGFb-1-induced processes were significantly suppressed by inhibiting ILK activity or by disrupting the ILK/Rictor complex using small-interfering RNA-mediated knockdown. Furthermore, we identified ILK/Rictor complex formation in cancer but not in normal cell types, and this was accompanied by ILK-dependent phosphorylation of Rictor on residue Thr1135. Inhibition of ILK partially reversed the basal mesenchymal phenotype of MDA-MB-231 cells and prevented EMT in MCF10A cells after TGFb-1 treatment. These data demonstrate a requirement for ILK function in TGFb-1-induced EMT in mammary epithelial cells and identify the ILK/Rictor complex as a potential molecular target for preventing/reversing EMT.
INTRODUCTION
Epithelial-to-mesenchymal transition (EMT) is the process by which epithelial cells downregulate cell --cell interactions and reorganize their cytoskeleton, acquiring mesenchymal properties and migrating to secondary sites. 1, 2 EMT has a significant role in tumor progression of epithelial cancers, as the loss of polarized epithelial phenotype and acquisition of mesenchymal properties promote tumor cell invasion into surrounding tissues and metastasis. 3 A better understanding of the mechanisms involved in EMT is crucial to develop efficacious treatments for tumor growth and metastasis. Transforming growth factor b-1 (TGFb-1) regulates growth, differentiation and epithelial transformation in the multiple processes of tumorigenesis, wound healing and embryogenesis. 4 TGFb-1 has a dual role in the development and progression of epithelial tumors, acting initially as a tumor suppressor and at later stages promoting growth, invasion and metastasis. 5 TGFb-1 regulation of EMT has been suggested to be dependent on integrin-linked kinase (ILK) function during kidney fibrosis. 6 Integrin-linked kinase is a widely expressed serine/threonine protein kinase, which localizes to focal adhesion plaques and centrosomes. 7, 8 ILK has a fundamental role in the regulation of cell survival, proliferation and migration 8 by connecting the cytoplasmic domains of b-integrins to the actin cytoskeleton, mediating integrin signaling in diverse cell types. ILK is activated and/or overexpressed in many types of cancers and is a critical regulator of breast cancer cell survival through direct phosphorylation and activation of Akt on residue Ser473, but is widely dispensable for the survival of normal breast epithelial cells, as shown by inhibition of ILK activity with a pharmacological smallmolecule ILK inhibitor (QLT0267). 9 Furthermore, ILK is a critical regulator of cancer cell survival through the Akt pathway by the interaction with Rictor, 10 a component of the mammalian target of rapamycin complex 2. In cancer cells, both mTORC2 and the ILK/Rictor complex are regulators of Akt Ser473 phosphorylation. 10 Both mTORC1 and mTORC2 are two structurally and functionally distinct multi-protein complexes. 11 They share the same catalytic subunit, the highly conserved phosphatidylinositol 3-kinaserelated Ser/Thr kinase mTOR, which is a major regulator of cell growth, proliferation and survival. 12 mTORC1 has an important role in the regulation of cell growth and protein synthesis by the ribosomal S6 kinases (S6Ks) and the eukaryotic initiation factor 4E-binding protein-1. 12, 13 The second complex, mTORC2, modulates cell proliferation and survival in response to growth factors by promoting phosphorylation and activation of Akt/PKB, proteinkinase C and serum glucocorticoid-induced protein kinase (SGK1). 12 As an mTORC2 and ILK/Rictor complex target, Akt has an important role in the control of mTORC1 activity in response to growth factors by releasing the inhibitory effect of tuberous sclerosis complex and PRAS40, positioning mTOR both upstream and downstream of Akt/PKB. 12 Little is known about the signaling cascades leading to activation of mTORC2, or any regulation that directly targets this complex. Rapamycin is a well-characterized immunosuppressant and potential anticancer drug. Rapamycin is a potent inhibitor of mTORC1, and hence S6Ks, but mTORC2 is considered to be rapamycin insensitive. 13 Interestingly, activation of mTORC2 by growth factor signaling is linked to specific phosphorylation of the complex component Rictor on residue Thr1135. This phosphorylation site is responsive to growth factor stimulation, phosphatidylinositol 3-kinase activity, rapamycin treatment and expression of mTOR or ILK.
14 The p70 ribosomal S6 kinase 1 (S6K1) is considered to be the principal kinase involved in Rictor phosphorylation at this site. 12, 13 Previous studies have shown that ILK is a key intracellular mediator of TGFb-1-induced EMT. 6 Targeting this signaling cascade could be an effective strategy for treatment of fibrotic kidney, 6 lung 15 or bladder cancer. 16 It has also been reported that overexpression of ILK induces EMT in mammary epithelial cells. 17 However, a role of ILK, if any, during TGFb-1-mediated EMT in cancer cells has not been established. In this study, we show that ILK inhibition prevents TGFb-1-induced EMT in NMe mouse, and MCF10A human mammary epithelial cells and identifying Snail and Slug as key EMT effectors of this pathway. Furthermore, we show a TGFb-1-dependent increase in the phosphorylation of Akt Ser473 and Rictor Thr1135 that requires ILK activity. Interestingly, TGFb-1 also induces Rictor expression and the formation of a complex between ILK and Rictor which is also dependent on ILK activity.
We have further characterized ILK-dependent phosphorylation of Rictor on Thr1135 in several human breast cell lines, and our results suggest that this phosphorylation is differentially regulated in normal and cancer cells. Pharmacological inhibition and genetic knockdown of ILK result in the downregulation of Rictor Thr1135 phosphorylation in breast cancer cells. Furthermore, the interaction between ILK and Rictor is malignancy dependent, as this complex is present in cancer cells but not in normal breast cell lines. In addition, ILK/Rictor complex formation is induced after EMT and can be prevented by inhibition of ILK.
RESULTS

Inhibition of ILK prevents TGFb-1-mediated EMT and cell migration in mammary epithelial cells
To investigate the role of ILK in EMT, we initially used the wellcharacterized normal mammary epithelial cell line, NMe. This E-cadherin-expressing cell population has been previously shown to undergo EMT after TGFb-1 stimulation 18 and is a good model to study mechanisms of TGFb-1-mediated EMT. Twenty-four hours after stimulation with TGFb-1, we detected changes in cell morphology, with the most striking response seen 48--72 h after treatment. Upon TGFb-1 treatment, NMe cell morphology alters from the typical 'cobblestone' epithelial morphology into the disorganized spindle-like appearance of mesenchymal cells. To investigate the role of ILK in TGFb-1-mediated EMT, we initially used a well-characterized and highly selective small-molecule inhibitor of ILK, QLT0267. 9, 19 Simultaneous incubation with TGFb-1 and QLT0267 significantly inhibited this observed EMT (Figure 1a ). Alpha-smooth muscle actin (a-SMA) is a mesenchymal marker that is upregulated during EMT. 3 As shown in Figure 1a , incubation with TGFb-1 resulted in an increase in a-SMA expression. However, co-incubation with TGFb-1 and QLT0267 resulted in a significant reduction in a-SMA expression. The epithelial marker b-catenin, which is required for the coupling of E-cadherin to the actin cytoskeleton, is downregulated during EMT. 20, 21 In control cells, b-catenin is clearly localized to cell--cell junctions. After TGFb-1 treatment, cell--cell junction localization of b-catenin is lost. However, co-incubation with QLT0267 results in significant recovery of cell --cell junctional localization of b-catenin as shown in Figure 1a .
A phenotypic hallmark of EMT is stimulation of cell migration. Therefore, we assessed NMe cell migration by using a scratch wound-healing assay. As shown in Figure 1b , NMe cells treated with TGFb-1 are highly migratory. However, inhibition of ILK activity by QLT0267 significantly reduced the observed TGFb-1-dependent increase in migration. Taken together, these data clearly indicate that ILK activity is fundamental in regulating TGFb-1-mediated EMT in NMe cells.
ILK mediates TGFb-1-induced EMT through Snail and Slug, independent of the Smad signaling pathway To study the mechanisms involved in the regulation of TGFb-1-mediated EMT through ILK in NMe cells, we used immunostaining to assess expression of the known EMT regulators, Snail and Slug. 22 As shown in Figure 2a , in untreated control cells, both Snail and Slug localize diffusely throughout the cell. Upon incubation with TGFb-1, both Snail and Slug are re-localized to the nucleus, their site of action as transcriptional regulators. In contrast, coincubation with TGFb-1 and QLT0267 significantly reduced Snail and Slug nuclear localization (Figure 2a ). Snail has previously been identified as the EMT regulator involved in ILK-mediated regulation of E-cadherin transcriptional repression in prostate cancer cells and intestinal epithelial cells. 1, 23 Slug has previously been characterized as a repressor of E-cadherin transcription, although the mechanisms involved in Slug activation and nuclear localization are still unknown. 24 Here, we show for the first time that ILK activity regulates TGFb-1-induced EMT through Snail and also through Slug, in NMe cells. Previous reports have identified Smad2 and Smad3 as downstream effectors of TGFb-1 receptor signaling. TGFb-1 receptors type I and II form tight complexes leading to phosphorylation of Smad2 and Smad3. Phosphorylated Smads partner with Smad4 and translocate to the nucleus where Smad complexes control transcription of target genes. 25 Accordingly, we investigated whether inhibition of ILK activity affected TGFb-1-mediated Smad nuclear localization. As shown in Figure 2b , TGFb-1 induced localization of Smad2/3 to the nucleus in concordance with previous reports. 25 However, co-incubation with TGFb-1 and QLT0267 did not block this observed nuclear translocation, suggesting that TGFb-1-mediated regulation of Smad2/3 is independent of ILK ( Figure 2b ). These results demonstrate that ILK activity is required for TGFb-1-mediated nuclear activation of Snail and Slug and that this activation is independent of Smad 2/3 activation.
TGFb-1 treatment stimulates Rictor expression and phosphorylation of Thr1135 and induces an ILK/Rictor interaction To gain further insights into the molecular mechanisms involved in ILK regulation of EMT, we evaluated the potential role of ILK and Rictor in TGFb-1-induced EMT of mammary epithelial cells. Both ILK and Rictor have been independently demonstrated to regulate aspects of EMT. 17, 23, 26 Furthermore, ILK and Rictor form a complex in several cancer cell lines and this complex can regulate Akt Ser473 phosphorylation. 10 In fact, stable knockdown of Rictor inhibits migration and EMT of colorectal cancer cells. 26 Therefore, we assessed expression of ILK and Rictor during TGFb-1-induced EMT using the NMe cell model. After 24 h TGFb-1 treatment, we observed a significant increase in the total levels of Rictor expression, but not in those of ILK expression (Figure 3a) . The observed increase in Rictor expression in these early stages of EMT, coupled with the demonstration of an interaction between ILK and Rictor 10 led us to study the interaction of these proteins before and after TGFb-1-mediated EMT induction. Endogenous ILK was immunoprecipitated from NMe cells after vehicle or TGFb-1 treatment for 24, 48 and 72 h. As shown in Figure 3b , vehicletreated, epithelial NMe cells did not show an interaction between ILK and Rictor. However, after TGFb-1 mediated-EMT induction, a complex between ILK and Rictor was formed in a time-dependent manner. Alternatively, cells were treated with TGFb-1 alone or in combination with the ILK inhibitor, QLT0267. Cells were then lysed and subjected to immunoprecipitation using an ILK antibody as described above. TGFb-1 treatment induced complex formation and Rictor precipitation with ILK, and interestingly this complex formation was prevented by QLT0267 (Figure 3c ), indicating that ILK function is necessary for both ILK/Rictor complex formation and TGFb-1-mediated EMT, possibly suggesting a requirement for the ILK/Rictor complex in the early stages of EMT.
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To further investigate the role of ILK in TGFb-1-mediated EMT, we assessed the levels of Rictor Thr1135 and Akt Ser473 phosphorylation, as both sites are known to be sensitive to ILK inhibition. 9, 14 Low basal phosphorylation of Rictor Thr1135 was observed in control cells. After 3 h of TGFb-1 treatment, Thr1135 phosphorylation was significantly increased. However, co-incubation with QLT0267 returned Thr1135 phosphorylation to basal levels ( Figure 3d ). Similarly, Ser473 was increased after TGFb-1 treatment, and co-incubation with QLT0267 reduced this response, with basal Akt Ser473 phosphorylation levels similar to control ( Figure 3d ). This is the first evidence for TGFb-1-mediated phosphorylation of Rictor and the requirement of ILK in this phosphorylation.
ILK/Rictor interaction is necessary for TGFb-1-induced EMT Although inhibition of ILK activity with the small-molecule inhibitor, QLT0267 disrupted the ILK/Rictor complex and inhibited TGFb-1-mediated EMT, the effect could be due to potential off-target effects of small molecules. To confirm the role of the ILK/ Rictor complex in TGFb-1-induced EMT, we disrupted the complex by silencing ILK or Rictor expression using small-interfering RNA (siRNA). Significant knockdown of ILK or Rictor in NMe cells transfected with appropriate siRNA was confirmed by western blotting (Figure 4a ) and immunofluorescence (Supplementary Figure 1) . Knockdown of ILK or Rictor expression inhibited TGFb-1 induction of the mesenchymal phenotype in NMe cells (Figure 4b) . Expression of the EMT markers a-SMA and b-catenin were also assessed by immunostaining (Figure 4c ). Specific knockdown of either ILK or Rictor expression inhibited TGFb-1-mediated induction of the mesenchymal marker a-SMA. In addition, TGFb-1 disrupted cell junction localization of the epithelial marker b-catenin. However, after ILK or Rictor knockdown, b-catenin localized persistently to the cell junctions (Figure 4c ). Furthermore, we observed that both ILK and Rictor expressions are required for Snail and Slug nuclear TGFb-1-induced EMT requires the ILK/Rictor complex I Serrano et al cells, but expression and cell junction localization are significantly rescued after co-incubation with QLT0267. Expression levels of a-SMA, a mesenchymal marker, were assessed by western blot (Figure 5b ). Vehicle-treated MCF10A cells express low basal levels of a-SMA. TGFb-1 treatment resulted in increased a-SMA expression, which returned to basal levels upon combined TGFb-1 and QLT0267 treatment. To confirm a role for ILK and Rictor in TGFb-1-induced EMT in this alternative cell type, we used siRNA to deplete ILK or Rictor in MCF10A cells. Knockdown of either ILK or Rictor expression blocked the observed mesenchymal phenotypic response to TGFb-1 treatment as shown in Figure 5c . To confirm these observations, E-cadherin expression was assessed by immunostaining. E-cadherin localization at cell junctions in control cells was downregulated after TGFb-1 treatment. However, knockdown of either ILK or Rictor resulted in significant rescue of E-cadherin expression and junctional localization (Figure 5c ). The mesenchymal marker a-SMA was also assessed by western blot (Figure 5c ). We observed an increase in a-SMA expression after TGFb-1 treatment, which was partially blocked with ILK siRNA depletion. Surprisingly, Rictor knockdown did not significantly block a-SMA expression. As a-SMA is also known as a vascular smooth muscle cell differentiation marker, 27 the continued expression of SMA in TGFb-1-treated, Rictordepleted cells may be due to a TGFb-1-mediated myoblastic differentiation, which is not regulated by Rictor. These results confirm that inhibition of ILK activity or knockdown of ILK or Rictor partially blocks the mesenchymal phenotype induced after TGFb-1 treatment in MCF10A cells.
Inhibition of ILK activity induces MET in a breast cancer cell line Epithelial --mesenchymal transition results in changes in cell polarity, cell isolation and acquisition of cell motility. 28 EMT is a reversible process and mesenchymal cells can also undergo the reverse process of mesenchymal-to-epithelial transition (MET). 29 To define the extent of the role of ILK in EMT and MET, we used the aggressive, mesenchymal breast cancer cell line MDA-MB-231. 30 A wound-healing scratch assay was used to assess MDA-MB-231 migration with and without ILK inhibition. As shown in Figure 6a , MDA-MB-231 cells migrate to close the wound over 24 h; however, incubation with the ILK inhibitor, QLT0267, inhibited this constitutive cell migration. Untreated MDA-MB-231 cells express low levels of the epithelial marker E-cadherin. However, after QLT0267 treatment, E-cadherin expression was significantly increased. Conversely, untreated MDA-MB-231 cells express the mesenchymal marker a-SMA. After ILK inhibition, a-SMA expression was significantly depleted (Figure 6b ). These results confirm that ILK inhibition can partially induce a normalized, epithelial phenotype in this aggressive mesenchymal breast cancer cell line.
An ILK/Rictor complex forms in breast cancer cell lines and is absent in normal breast epithelial cells We have previously identified the ILK/Rictor complex as being required for Akt Ser473 phosphorylation and cell survival regulation in human breast cancer cell lines. 10 To further investigate the interaction between ILK and Rictor, as well as Rictor Thr1135 phosphorylation in breast cancer cells versus normal epithelial cells, we immunoprecipitated ILK from different human breast cancer and normal breast cell lines. ILK and Rictor were found to form a complex in several breast cancer cell lines. Furthermore, Rictor, but not mTOR, was copurified with ILK in these cell lines (Figure 7a ). We also sought to characterize ILK and Rictor interaction in normal breast cell lines. Using the same experimental conditions, we were unable to identify an ILK/Rictor complex in MCF10A and hTERT normal breast epithelial cell lines (Figure 7b ). To further investigate ILK/Rictor interaction in cancer (Figure 7c ). Second, we used siRNA to specifically knock down expression of ILK in the MDA-MB-231 and MCF7 breast cancer cell lines. Knockdown of ILK resulted in inhibition of Rictor phosphorylation after serum stimulation in both cancer cell lines (Figure 7d) . Furthermore, it has previously been shown that phosphorylation of Rictor on residue Thr1135 creates a 14 --3 --3-binding site. 12, 31, 32 To demonstrate that ILK activity is required for Rictor phosphorylation on Thr1135, we immunoprecipitated ILK and blotted for 14 --3 --3 in the presence or absence of the ILK inhibitor. Control cells showed an interaction between ILK and 14 --3 --3; however, inhibition of ILK activity resulted in loss of 14 --3 --3 from the ILK interacting complex (Figure 7e ). These data confirm the requirement of ILK activity for Rictor Thr1135 phosphorylation and 14 --3 --3 complex formation. ILK expression is positively associated with tumor aggressiveness and metastasis. Having assessed ILK and Rictor interaction in breast cancer cell lines, these results suggest a differential role for this complex in cancer versus normal cells. These findings also correlate with data discussed earlier, confirming that NMe cells undergo EMT and convert from a benign to a malignant phenotype. Taken together, these results suggest that ILK/Rictor interaction and Rictor phosphorylation are potential regulators of TGFb-1-induced EMT, through a Snail-and Slugdependent mechanism (Figure 8 ), and occur in cancer but not in normal epithelial cells. This hypothesis would therefore suggest the ILK/Rictor complex as a cancer-specific molecular target.
DISCUSSION
Transforming growth factor-b-1 has been shown to induce EMT through downstream targets, including Smad 2/3, 33 AP-1 family members, 34 Rho-A, 35 phosphatidylinositol 3-kinase 36 and ILK. been shown that Smad2, 3 and 4 bind microtubules in several cell lines. 38 Despite previous data demonstrating ILK localization to centrosomes, 7 we could not identify an interaction between ILK and the microtubule-binding protein Smad in TGFb-1-treated cells. However, we demonstrate here that ILK inhibition can block TGFb-1-induced nuclear translocation of the EMT regulator Snail, confirming previous reports demonstrating ILK repression of E-cadherin expression through Snail and poly (ADP-ribose) polymerase-1. 1 In addition, we show, for the first time that ILK can also regulate nuclear activation of Slug during TGFb-1-mediated EMT. EMT promotes cell migration, and ILK inhibition suppresses TGFb-1-induced cell migration, confirming the requirement for ILK activity in EMT, as previously suggested. 3, 6, 37, 39 However, little is known about the role of ILK in mammary epithelial cells undergoing EMT, a process that has been linked to malignant behavior and metastasis. 40 Previously, we have shown that ILK overexpression by transfection of exogenous ILK promotes mesenchymal transformation of mammary epithelial cells. 17 The data presented in this study expand on this observation, demonstrating that ILK function has a fundamental role in mediating mammary epithelial cell TGFb-1-induced EMT and cell migration. Furthermore, we show for the first time that TGFb-1 induces Rictor expression and an ILK/Rictor interaction, and that this interaction is dependent on ILK activity. These data are in agreement with a recent study, which demonstrated that Rictor is overexpressed in primary colorectal cancer and suggested that mTORC1 and mTORC2 are regulators of EMT and metastasis. 26 Here, we show that total Rictor expression is induced after 24 h TGFb-1 treatment, in parallel with ILK/Rictor complex formation. Using the QLT0267 ILK inhibitor, we were able to disrupt this complex, temporally correlated with disruption of TGFb-1 induced EMT. Furthermore, we observed similar results by specifically depleting ILK or Rictor, confirming that blockade of the ILK/Rictor complex by Rictor or ILK knockdown suppresses TGFb-1 induced EMT, and confirming the importance of the ILK/Rictor complex in the early stages of EMT. In addition, using the human epithelial MCF10A cell line, we were able to reproduce the results observed in NMe mouse epithelial cells and to verify that both ILK and Rictor are required for TGFb-1-induced EMT. Although investigating EMT in human cells, we observed that QLT0267 treatment of MDA-MB- Figure 5 . TGFb-1-mediated EMT is dependent on ILK and Rictor in human MCF10A cells. Cells were treated with DMSO, TGFb-1 (5 ng/ml) or TGFb-1 with QLT0267 (10 mM). (a) After 24 h, the confluent cell monolayer was wounded and wound closure was captured by phase-contrast microscopy at the indicated time points. Scale bar ¼ 100 mm. (b) After 48 h, cells were fixed and subjected to immunofluorescence staining of epithelial markers. Arrows indicate localization of E-cadherin at adherens junctions. Scale bar ¼ 50 mm. Alternatively, cells were lysed and subjected to western blotting to assess a-SMA expression and GAPDH as a loading control. (c) MCF10A cells were transfected with nonsilencing control (CT), ILK or Rictor siRNA. After 48 h of indicated treatments, bright field pictures were captured to confirm cell morphology characteristics. Scale bar ¼ 20 mm. Cells were then fixed and stained for E-cadherin. Scale bar ¼ 50 mm. Alternatively, cells were lysed and a-SMA expression assessed by western blot with GAPDH as a loading control. We have demonstrated for the first time that the ILK/Rictor complex forms in cancerous but not in normal cell types, suggesting a differential role of this complex between normal and cancer cell phenotypes, thus identifying an interesting cancerspecific target. Although the ILK/Rictor complex was predominantly found to be present in the more aggressive, basal-type breast cancer cell lines, and also in other 'mesenchymal' cancer cell lines such as PC-3 prostate cancer cells, 10 we were surprised to find here that this complex was also present in the more 'epithelial' and luminal-type breast cancer cell line, MCF-7. This suggests that that ILK/Rictor complex formation may occur as a result of activation of other pathways independent of TGFb-1, and may become more relevant in regulating processes such as EMT with further mutational and epigenetic events. These data also suggest that ILK/Rictor complex formation is necessary, but not sufficient, for TGFb-1-induced EMT. It will be interesting to investigate whether ILK/Rictor is involved in other signaling pathways, such as Wnt, which induce EMT in mammary epithelial and other epithelial cell types.
We have furthermore confirmed the ILK/Rictor interaction in breast cancer cell lines by our characterization of Rictor Thr1135 phosphorylation. Using the ILK small-molecule inhibitor QLT0267 or siRNA to knock down ILK expression, we show how, in breast cancer cell lines, Rictor Thr1135 phosphorylation is ILK dependent. Previous studies have investigated the differential requirement of ILK for Ser473 Akt phosphorylation in cancer versus normal breast cell lines showing that ILK inhibition induces apoptosis in cancer cells but not in normal cells. 9 Previous reports have focused on the role of Rictor Thr1135 phosphorylation in the regulation of mTORC2 function; however, others have reported that Rictor can be phosphorylated outside the mTORC2 assembly as Rictor Thr1135 has been observed in mTORC2-deficient cells. We have previously described the differential capacity of Rictor to interact with mTOR and ILK in human cancer cells. Here, we show that ILK/Rictor interaction is constitutive in breast cancer cells, where an ILK-dependent phosphorylation of Rictor Thr1135 was observed. In concordance with these results, the ILK/Rictor interaction may explain the preferential dependence of breast cancer cells versus normal cells on ILK for Akt activation and cell survival shown in previous reports. 9 Although we have identified a novel pathway for TGFb-1-induced EMT in mammary epithelial cells that involves the formation of an ILK/Rictor complex, the precise molecular mechanisms involved downstream of this complex in the nuclear activation of the EMT regulators, Snail and Slug, remain to be determined. In addition, the role of ILK-mediated phosphorylation of Rictor at Thr1135, and the subsequent binding of 14 --3 --3 in TGFb-1-mediated EMT remains to be determined as this will require the generation of stable Rictor-depleted epithelial cells. However, the data shown in this paper clearly demonstrate that ILK activity-dependent formation of the ILK/Rictor complex is required for TGFb-1-mediated EMT and that this complex is formed constitutively in cancer cell lines but not in normal epithelial cells. One possible pathway downstream of the complex may involve either ILK or Akt-dependent phosphorylation and # denotes significance at Po0.05 versus serum, as determined by Student's t-test. (d) MDA-MB-231 and MCF7 cells were treated with non-silencing control (CT) or ILK siRNA. Cells were lysed and subjected to western blotting to assess Rictor phosphorylation and confirm ILK knockdown. Representative blots are shown. Graph represents densitometric analysis of three independent experiments. * Denotes significance at Po0.05 versus control (CT) siRNA;
# denotes significance at Po0.05 versus non serum treatment as determined by Student's t-test. (e) NMe cells were serum starved for 24 h, and then stimulated with 30 min serum treatment, lysed and endogenous ILK immunoprecipitated (compared with IgG control). Precipitates were analyzed by western blot.
TGFb-1-induced EMT requires the ILK/Rictor complex I Serrano et al inactivation of glycogen synthase kinase-3b (GSK-3b), which would lead to inhibition of Snail phosphorylation on Ser246 and its subsequent stabilization and nuclear accumulation. Both ILK and Akt are known to phosphorylate and inactivate GSK-3b 41 and GSK-3b, the 'guardian of the epithelial state', has been shown to regulate Snail degradation through its phosphorylation on Ser246. 42 --44 A possible pathway for TGFb-1-mediated EMT through the ILK/Rictor complex is depicted in Figure 8 .
In summary, we have demonstrated that the ILK/Rictor complex, which is only present in a cancer-specific background, is induced in mammary epithelial cells after TGFb-1-mediated EMT and is dependent on ILK activity. Thus, the ILK/Rictor complex is an attractive regulatory target for the inhibition or prevention of TGFb-1-induced EMT in mammary epithelial cells and in inducing MET in aggressive cancer cells.
MATERIALS AND METHODS
Cell culture and treatment
NMe cells were cultured as described previously. 45 Where appropriate, cells were incubated in serum-free media with 5 ng/ml human recombinant TGFb1 (R&D Systems, Burlington, ON, Canada) or vehicle (4 mM HCl containing 1 mg/ml bovine serum albumin) for various periods of time as specified in the text. Co-incubation with dimethyl sulfoxide or 10 mM QLT0267 was also carried out as appropriate. Human breast cancer cells (MDA-MB-231, MDA-MB-468, BT549 and MCF7) were cultured in high glucose Dulbecco's modified Eagle's medium (Invitrogen, Burlington, ON, Canada) with 2 mmol/l L-glutamine and 10% fetal bovine serum (Invitrogen). Normal human epithelial MCF10A and 184hTERT cells were cultured as described previously. 46, 47 To examine Rictor phosphorylation, cells were serum starved for 24 h, then treated with or without 10% fetal bovine serum for 30 min. Cells were incubated with QLT0267 at concentrations specified in the text (QLT, Vancouver, BC, Canada), LY294002 (Sigma-Aldrich, Oakville, ON, Canada) or rapamycin (LC Laboratories, Woburn, MA, USA), 5 h, 1 h and 30 min. respectively, previous to serum stimulation. Control cells were incubated with dimethyl sulfoxide vehicle (Sigma-Aldrich).
siRNA transfection Cells were transfected using SilentFect (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions. Cell monolayers were incubated with 100 mM ILK or Rictor siRNA overnight, passaged and 24 h later, cells were transfected again for a total of 72 h before various treatments as noted in the text.
Cell lysis and immunoprecipitation
Cells were harvested and lysed as described previously. 10 For immunoprecipitation experiments, cell lysis was carried out using 0.3% CHAPS buffer. 10, 48 Protein concentrations were determined using the bicinchoninic acid assay (Pierce Biotechnology, Rockford, IL, USA). Immunoprecipitation of 1 --2 mg protein was carried as described previously 10 Western blot analysis Figure 8 . ILK and Rictor interact to regulate TGFb-1-induced EMT. Data presented here demonstrate a novel signaling pathway for TGFb-1-induced EMT. After TGFb-1 treatment, Rictor expression is increased and a complex is formed between Rictor and ILK. Rictor phosphorylation on Thr1135 is induced and is dependent on ILK activity. The ILK/Rictor complex, through Snail and Slug nuclear translocation, is required for TGFb-1-mediated EMT. Dashed arrows indicate a proposed pathway, which may involve either ILK-or Aktdependent phosphorylation of GSK-3b.
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